Also trades as: 0HIY.L (LSE) · $vol 0M
ATRA NASDAQ
Atara Biotherapeutics, Inc.
1W: -9.4%
1M: -0.8%
3M: +3.0%
YTD: -53.3%
1Y: -42.7%
3Y: -75.8%
5Y: -97.8%
$8.30
-0.05 (-0.60%)
Pre-Market: $8.67 (+0.37, +4.46%)
Weekly Expected Move ±10.1%
$7
$8
$9
$9
$10
Credit Risk of going bust: higher than 91% of companies Debt: 10.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.25 (down 97%), Atara Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $9.9M against a stock market value of $83.3M.
Distance to default 1.49 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.9M (short-term plus half of long-term), stock volatility 142.0%; Altman Z'' -317.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.25 (down 97%), Atara Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $9.9M against a stock market value of $83.3M.
Distance to default 1.49 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.9M (short-term plus half of long-term), stock volatility 142.0%; Altman Z'' -317.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships13
As Filer
counterparties named
1
As Counterparty
mentioned by others
4
Rel. Types
2021-10-04
Earliest Filing
2026-02-23
Latest Filing
partner: 7
investor: 2
supplier: 2
acquirer: 2
Counterparties (Filed by ATRA)
13 relationshipsCompanies named in ATRA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| HCR Molag Fund, L.P. | — | investor | Amendment to Purchase and Sale Agreement regarding milestone payment due date extension | 2026-02-23 | View |
| Pierre Fabre Medicament | — | partner | Amendment to commercialization agreement reducing milestone payments | 2026-01-02 | View |
| Pierre Fabre Medicament | — | partner | Agreement amendment transferring manufacturing responsibility and remediation costs for tabelecleucel. | 2025-04-04 | View |
| Pierre Fabre Medicament | — | partner | Partnered with Atara Biotherapeutics for an expanded global commercialization license of tabelecleucel (tab-cel) with up | 2023-11-01 | View |
| Pierre Fabre Laboratories | — | partner | Partnered with Atara Biotherapeutics for an expanded global commercialization license of tabelecleucel (tab-cel) with up | 2023-11-01 | View |
| HCR Molag Fund, L.P. | — | investor | Agreed to pay $31M for rights to future royalties and milestones from Pierre Fabre | 2022-12-20 | View |
| Pierre Fabre Medicament | — | supplier | Obligated to pay royalties and milestones to Atara Biotherapeutics under Commercialization Agreement | 2022-12-20 | View |
| Pierre Fabre Medicament | — | partner | Amendment to Commercialization Agreement for tabelecleucel product commercialization and milestone payment | 2022-09-28 | View |
| Bayer AG | BYMOF | partner | Terminated exclusive license agreement for ATA2271 and ATA3271 CAR T-cell therapies and entered into a termination and p | 2022-08-08 | View |
| Charles River Laboratories | CRL | supplier | Extended the Commercial Manufacturing Agreement term through January 31, 2023. | 2022-08-08 | View |
| FUJIFILM Diosynth Biotechnologies California, Inc. | — | acquirer | Acquired Atara Biotherapeutics' T-Cell Operations and Manufacturing facility assets for approximately $100 million. | 2022-04-04 | View |
| FUJIFILM Holdings America Corporation | — | acquirer | Named as a limited party to the asset purchase agreement for the acquisition of Atara Biotherapeutics' manufacturing ass | 2022-04-04 | View |
| Pierre Fabre Medicament | — | partner | Atara Biotherapeutics entered into a Commercialization Agreement granting Pierre Fabre an exclusive license to commercia | 2021-10-04 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ATRA in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-12 | Earnings Release | View | |
| 2026-06-26 | Officer/Director Change | View | |
| 2026-06-12 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-12 | Exhibits | View | |
| 2026-05-07 | Other Events | View | |
| 2026-05-01 | Delisting Notice | View | |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-12 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-03 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-23 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2026-01-12 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-02 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-07 | Costs Associated with Exit or Disposal Activities | View | |
| 2025-09-04 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-14 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-11 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-16 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-15 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR